Topical Myristyl Nicotinate Cream on the Skin of Healthy Volunteers
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00619060 |
Recruitment Status :
Completed
First Posted : February 20, 2008
Results First Posted : March 10, 2016
Last Update Posted : March 10, 2016
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming. The use of topical myristyl nicotinate cream may stop skin cancer from forming.
PURPOSE: This randomized phase I trial is studying the side effects and best way to give topical myristyl nicotinate cream on the skin of healthy volunteers.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Healthy | Drug: Topical Myristyl Nicotinate Cream Drug: Placebo | Phase 1 |
OBJECTIVES:
- To determine if topical myristyl nicotinate (MN) is a safe, tolerable treatment in healthy volunteers.
- To determine if topically administered MN cream is associated with any significant local or systemic toxicity in normal human subjects in a one-month period.
OUTLINE: Participants are randomized to 1 of 2 treatment arms and serve as their own controls.
- Arm I: Participants apply topical myristyl nicotinate to one forearm and topical placebo to the other forearm once daily for 4 weeks.
- Arm II: Participants receive treatment as in arm I but on opposite forearms. All participants undergo blood collection for chemistry analysis (SMA-20 and CBC) at baseline and at 2 and 4 weeks.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 22 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Prevention |
Official Title: | A Phase I Study of Topical Myristyl Nicotinate Cream on Human Skin in Healthy Volunteers |
Study Start Date : | August 2007 |
Actual Primary Completion Date : | July 2008 |
Actual Study Completion Date : | July 2008 |

Arm | Intervention/treatment |
---|---|
Experimental: Myristyl (right), Placebo (Left)
Participants apply topical myristyl nicotinate to the right forearm and topical placebo to the left forearm once daily for 4 weeks; Myristyl (Right), Placebo (Left) Topical Myristyl Nicotinate Cream and Placebo
|
Drug: Topical Myristyl Nicotinate Cream
Participants apply topical myristyl nicotinate to one forearm once daily for 4 weeks.
Other Names:
Drug: Placebo Participants apply topical placebo to one forearm once daily for 4 weeks. |
Experimental: Myristyl (Left), Placebo (Right)
Participants apply topical myristyl nicotinate to the left forearm and topical placebo to the right forearm once daily for 4 weeks; Myristyl (Left), Placebo (Right)Topical Myristyl Nicotinate Cream and Placebo
|
Drug: Topical Myristyl Nicotinate Cream
Participants apply topical myristyl nicotinate to one forearm once daily for 4 weeks.
Other Names:
Drug: Placebo Participants apply topical placebo to one forearm once daily for 4 weeks. |
- Participants With Adverse Events by Treatment. [ Time Frame: 30 Days ]Comparison of number of participants with adverse events by treatment.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Subjects 18 years of age or older with normal skin
- Have used no topical medications on the skin of the upper extremities, except for emollients or sunscreens, for at least 30 days prior to study entry
- Agree to limit sun exposure as much as possible and wear protective clothing on the forearms in place of using sunscreens or moisturizers
- Ability to understand and willingness to sign an informed consent before initiation of therapy after the nature of the study has been explained to them
- Females must be surgically sterile by hysterectomy or post menopausal
Exclusion Criteria:
- Subjects with no signs of inflammation or irritation of the skin on the forearms
- Subjects with prior history of actinic keratosis or skin cancer on the forearm
- Females of child bearing potential
- Subjects with any concurrent therapy (e.g., retinoids, fluorouracil) on the forearms that may interfere with clinical evaluations
- Subjects taking oral supplemental niacin, by itself or in the form of a multi-vitamin that exceeds 40 mg/day
- No known immunosuppression by virtue of medication or disease, including AIDS patients, subjects taking oral prednisone, and subjects on immunosuppressants/immunomodulators( cyclosporine, chemotherapeutic agents, or biologic therapy), determined by the examining investigator/co-investigator
- Uncontrolled intercurrent illness including, but not limited to any of ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Subjects who have had invasive cancer within the past 5 years
- Skin conditions felt by the study physician to contraindicate enrollment including, but not limited to, psoriasis or atopic dermatitis within a proposed treatment area
- Less than 30 days since prior and no concurrent or planned participation in another clinical trial

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00619060
United States, Arizona | |
Arizona Cancer Center at University of Arizona Health Sciences Center | |
Tucson, Arizona, United States, 85724-5024 |
Study Chair: | Clara Curiel, MD | University of Arizona |
Responsible Party: | University of Arizona |
ClinicalTrials.gov Identifier: | NCT00619060 |
Other Study ID Numbers: |
CDR0000582627 P30CA023074 ( U.S. NIH Grant/Contract ) UARIZ-BIO-07-085 ( Other Identifier: UA IRB No. ) |
First Posted: | February 20, 2008 Key Record Dates |
Results First Posted: | March 10, 2016 |
Last Update Posted: | March 10, 2016 |
Last Verified: | September 2014 |
skin cancer healthy, no evidence of disease |
Niacin Nicotinic Acids Hypolipidemic Agents Antimetabolites Molecular Mechanisms of Pharmacological Action Lipid Regulating Agents |
Vasodilator Agents Vitamin B Complex Vitamins Micronutrients Physiological Effects of Drugs |